This technology is a collection of monoclonal potent antibodies that target epitopes of SARS-CoV-2 and other coronaviruses for COVID-19 prophylaxis and therapeutic applications.
The efficacy of current vaccines and monoclonal antibody therapeutics has been undermined by the emergence of SARS-CoV-2 variants carrying spike protein mutations that enable immune evasion, reducing the neutralization capacity of existing treatments. Therapies currently on the market that prevent and treat SARS-CoV-2 include antiviral treatments, monoclonal antibodies, and immunizations. As new variants of concern emerge, there is a critical need for antibody therapeutics that retain potency across diverse viral lineages, target multiple conserved epitopes, and can be deployed individually or in combination to maintain clinical efficacy.
This technology describes six monoclonal antibodies with potent antiviral activity against SARS-CoV-2 (including multiple variants of concern) and three monoclonal antibodies with potent antiviral activity against other SARS-like coronaviruses. These antibodies were isolated from memory B cells of SARS-CoV-2–infected individuals (vaccinated and unvaccinated) selected for the strongest neutralizing activity, sequenced, and expressed in vitro to produce recombinant monoclonal antibodies with defined heavy and light chain amino acid sequences. Monoclonal antibodies were developed from the cloned sequences of these highly neutralizing B cells and expressed in vitro.
These antibodies have been validated in both pseudotyped and live virus assays in vitro to test neutralization against nine SARS-CoV-2 variants.
Patent Pending (US20240343781)
IR CU22012
Licensing Contact: Kristin Neuman